The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

ESR1 mutations are rarely found in primary tumors but develop in metastatic settings under pressure from aromatase inhibitors, conferring resistance. This evolution necessitates serial, plasma-based genotyping upon each disease progression to identify these actionable mutations as they emerge.

The SERENA-6 strategy of switching to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical progression—is a novel concept. It forces oncologists to grapple with the idea of 'molecular progression' and whether this biomarker-led switch truly alters the disease's natural history.

An acquired ESR1 mutation in metastatic breast cancer, while indicating resistance to prior therapy, also confirms the tumor remains dependent on the estrogen receptor pathway. This paradoxical finding makes the mutation an ideal biomarker for predicting success with next-generation endocrine agents like oral SERDs.

ESR1 mutations in breast cancer are acquired alterations, meaning they can be missed by a single test. The speaker advocates for serial testing, especially after disease progression, using blood-based ctDNA analysis. This dynamic monitoring approach is essential for identifying patients who become eligible for targeted therapies over time.

The SERENA-6 study represents a fundamental shift in oncology care. It tests the principle of intervening with therapy based on detecting an ESR1 mutation in ctDNA (molecular progression) *before* the patient shows signs of disease advancement on imaging scans (radiological progression), a new proactive treatment paradigm.

Not all mutations are equal. PIK3CA alterations are often present from the start (truncal mutations), indicating a more aggressive cancer. In contrast, ESR1 mutations are typically acquired later as a direct mechanism of resistance to endocrine therapy, making repeat testing after disease progression crucial.

An ESR1 mutation locks the estrogen receptor in a permanently "on" state, independent of estrogen. This renders aromatase inhibitors (AIs) ineffective but means therapies that degrade the receptor itself, like SERDs, can still be effective treatment options.

The SERINA-6 trial supports a paradigm shift: proactively screening for ESR1 mutations via blood test and switching to camisestrant upon detection, even without radiological progression. This early switch based on molecular signals nearly doubled median progression-free survival from 9 to 16 months.